|
MX361680B
(es)
|
2012-12-13 |
2018-12-13 |
Aduro Biotech Inc |
Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso.
|
|
EP4398254A2
(en)
|
2013-04-29 |
2024-07-10 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for altering second messenger signaling
|
|
PL2996473T3
(pl)
|
2013-05-18 |
2020-06-01 |
Aduro Biotech, Inc. |
Kompozycje i sposoby aktywacji sygnałowania zależnego od „stymulatora genu interferonu”
|
|
PE20170198A1
(es)
|
2014-06-04 |
2017-04-08 |
Glaxosmithkline Ip Dev Ltd |
Dinucleotidos ciclicos como moduladores de sting
|
|
ES2764178T3
(es)
*
|
2014-12-16 |
2020-06-02 |
Kayla Therapeutics |
Dinucleótidos cíclicos fluorados para inducción de citocinas
|
|
GB201501462D0
(en)
|
2015-01-29 |
2015-03-18 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
WO2016145102A1
(en)
|
2015-03-10 |
2016-09-15 |
Aduro Biotech, Inc. |
Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
|
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
MX2018001814A
(es)
|
2015-08-13 |
2018-05-07 |
Merck Sharp & Dohme |
Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
|
|
EP3359675B1
(en)
|
2015-10-07 |
2024-01-03 |
Nant Holdings IP, LLC |
Activation of immune-related signalling pathways in cells via optofection
|
|
CR20180286A
(es)
|
2015-12-03 |
2018-07-16 |
Glaxosmithkline Ip Dev Ltd |
Dinucleotidos de purina cíclicos como moduladores de sting
|
|
MX2018008266A
(es)
|
2016-01-11 |
2019-01-31 |
Innate Tumor Immunity Inc |
Dinucleotidos ciclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferon (sting) tales como cancer.
|
|
SG10201912074PA
(en)
|
2016-03-18 |
2020-02-27 |
Immune Sensor Llc |
Cyclic di-nucleotide compounds and methods of use
|
|
EP3448393A1
(en)
*
|
2016-04-25 |
2019-03-06 |
Invivogen |
Novel complexes of immunostimulatory compounds, and uses thereof
|
|
US10696985B1
(en)
|
2016-06-06 |
2020-06-30 |
Vanderbilt University |
Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery
|
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
IL264049B2
(en)
*
|
2016-07-06 |
2023-11-01 |
Sperovie Biosciences Inc |
Compounds, preparations and methods for treating the disease
|
|
MX2019000660A
(es)
*
|
2016-07-15 |
2019-10-02 |
Sperovie Biosciences Inc |
Compuestos, composiciones y métodos para el tratamiento de enfermedades.
|
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
|
US10537590B2
(en)
*
|
2016-09-30 |
2020-01-21 |
Boehringer Ingelheim International Gmbh |
Cyclic dinucleotide compounds
|
|
SG10202008647TA
(en)
|
2016-10-04 |
2020-10-29 |
Merck Sharp & Dohme |
BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
|
|
US11001605B2
(en)
|
2016-10-07 |
2021-05-11 |
Biolog Life Science Institute Gmbh & Co. Kg |
Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways
|
|
JOP20170188A1
(ar)
*
|
2016-11-25 |
2019-01-30 |
Janssen Biotech Inc |
ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
|
|
JOP20170192A1
(ar)
|
2016-12-01 |
2019-01-30 |
Takeda Pharmaceuticals Co |
داي نوكليوتيد حلقي
|
|
JP2018090562A
(ja)
*
|
2016-12-01 |
2018-06-14 |
武田薬品工業株式会社 |
環状ジヌクレオチド
|
|
US20200113924A1
(en)
*
|
2016-12-20 |
2020-04-16 |
Merck Sharp & Dohme Corp. |
Cyclic dinucleotide sting agonists for cancer treatment
|
|
KR20190126283A
(ko)
*
|
2016-12-22 |
2019-11-11 |
마브파마, 인크. |
포스포디에스테라아제 저해제 및 미생물 치료 방법
|
|
US20200055883A1
(en)
|
2017-02-17 |
2020-02-20 |
Eisai R&D Management Co., Ltd. |
Cyclic di-nucleotides derivative for the treatment of cancer
|
|
EP3585379A4
(en)
|
2017-02-21 |
2020-12-02 |
Board of Regents, The University of Texas System |
CYCLIC DINUCLEOTIDES AS AGONISTS OF THE STIMULATOR OF INTERFERON-DEPENDENT SIGNALING
|
|
CN110651036A
(zh)
|
2017-03-20 |
2020-01-03 |
健诺西生物科学公司 |
治疗方法
|
|
JOP20190218A1
(ar)
*
|
2017-03-22 |
2019-09-22 |
Boehringer Ingelheim Int |
مركبات ثنائية النيوكليوتيدات حلقية معدلة
|
|
CN118267470A
(zh)
|
2017-04-13 |
2024-07-02 |
赛罗帕私人有限公司 |
抗SIRPα抗体
|
|
AU2018252193A1
(en)
|
2017-04-14 |
2019-10-17 |
Tallac Therapeutics, Inc. |
Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
|
|
WO2018198084A1
(en)
*
|
2017-04-27 |
2018-11-01 |
Lupin Limited |
Cyclic di-nucleotide compounds with tricyclic nucleobases
|
|
AR113224A1
(es)
|
2017-04-28 |
2020-02-19 |
Novartis Ag |
Conjugados de anticuerpo que comprenden un agonista de sting
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
WO2018208667A1
(en)
|
2017-05-12 |
2018-11-15 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
|
AU2018277559A1
(en)
|
2017-05-30 |
2019-10-17 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent
|
|
KR20200032180A
(ko)
*
|
2017-07-28 |
2020-03-25 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
|
WO2019027858A1
(en)
|
2017-08-04 |
2019-02-07 |
Merck Sharp & Dohme Corp. |
BENZO [B] STING THIOPHEN AGONISTS FOR THE TREATMENT OF CANCER
|
|
JP2020529421A
(ja)
|
2017-08-04 |
2020-10-08 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ
|
|
EP3692048A4
(en)
*
|
2017-08-30 |
2021-10-20 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS
|
|
KR20200039796A
(ko)
*
|
2017-08-31 |
2020-04-16 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
|
WO2019051489A1
(en)
|
2017-09-11 |
2019-03-14 |
Sperovie Biosciences, Inc. |
COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
|
|
US11584774B2
(en)
|
2017-09-11 |
2023-02-21 |
F-star Therapeutics, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
|
WO2019069275A1
(en)
*
|
2017-10-05 |
2019-04-11 |
Glaxosmithkline Intellectual Property Development Limited |
STING AGONIST ADMINISTRATION METHODS
|
|
JP7254821B2
(ja)
*
|
2017-10-16 |
2023-04-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗がん剤としての環状ジヌクレオチド
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
BR112020009126A2
(pt)
|
2017-11-10 |
2020-10-20 |
Takeda Pharmaceutical Company Limited |
compostos do modulador sting e métodos de fabricação e uso
|
|
EA038805B1
(ru)
*
|
2017-11-21 |
2021-10-21 |
Такеда Фармасьютикал Компани Лимитед |
Циклические динуклеотиды в качестве агонистов sting (стимулятор генов интерферона)
|
|
US11203610B2
(en)
|
2017-12-20 |
2021-12-21 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
WO2019125974A1
(en)
|
2017-12-20 |
2019-06-27 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
|
JP7037667B2
(ja)
|
2017-12-20 |
2022-03-16 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． |
Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド
|
|
EP3505527A1
(en)
|
2017-12-29 |
2019-07-03 |
Invivogen |
Cyclic dinucleotides for cytokine induction
|
|
TWI818943B
(zh)
*
|
2018-01-04 |
2023-10-21 |
中央研究院 |
用於增加療效之可與細胞結合的免疫佐劑
|
|
AU2019237508A1
(en)
|
2018-03-23 |
2020-10-01 |
Lonza Sales Ag |
Extracellular vesicles comprising STING-agonist
|
|
WO2019180683A1
(en)
|
2018-03-23 |
2019-09-26 |
Takeda Pharmaceutical Company Limited |
Sting modulator compounds with sulfamate linkages, and methods of making and using
|
|
CN111989338A
(zh)
|
2018-03-27 |
2020-11-24 |
勃林格殷格翰国际有限公司 |
修饰的环二核苷酸化合物
|
|
EP3774834A1
(en)
|
2018-03-27 |
2021-02-17 |
Boehringer Ingelheim International GmbH |
Cyclic dinucleotide compounds containing 2-aza-hypoxanthine or 6h-pytazolo[1,5-d][1,2,4]triazin-7-one as sting agonists
|
|
JP7326319B2
(ja)
|
2018-04-03 |
2023-08-15 |
メルク・シャープ・アンド・ドーム・エルエルシー |
Ｓｔｉｎｇアゴニストとしてのベンゾチオフェン類及び関連する化合物
|
|
WO2019195063A1
(en)
|
2018-04-03 |
2019-10-10 |
Merck Sharp & Dohme Corp. |
Aza-benzothiophene compounds as sting agonists
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
SG11202011434SA
(en)
|
2018-06-01 |
2020-12-30 |
Eisai R&D Man Co Ltd |
Methods for the treatment of bladder cancer
|
|
US11691990B2
(en)
|
2018-08-16 |
2023-07-04 |
Eisai R&D Management Co., Ltd |
Salts of compounds and crystals thereof
|
|
EP3841112A1
(en)
|
2018-08-24 |
2021-06-30 |
Codiak BioSciences, Inc. |
Extracellular vesicles targeting dendritic cells and uses thereof
|
|
CA3111784A1
(en)
|
2018-09-12 |
2020-03-19 |
Silverback Therapeutics, Inc. |
Methods and compositions for the treatment of disease with immune stimulatory conjugates
|
|
BR112021005655A2
(pt)
|
2018-09-27 |
2021-06-29 |
Pierre Fabre Medicament |
ligantes à base de sulfomaleimida e conjugados correspondentes
|
|
EP3868773A4
(en)
*
|
2018-10-12 |
2022-07-13 |
Shanghai Jemincare Pharmaceuticals Co., Ltd. |
CYCLIC DINUCLEOTIDE COMPOUND AND ITS APPLICATIONS
|
|
EP3873484B1
(en)
|
2018-10-29 |
2023-08-23 |
Venenum Biodesign, LLC |
Novel sting agonists
|
|
US11110106B2
(en)
|
2018-10-29 |
2021-09-07 |
Venenum Biodesign, LLC |
Sting agonists for treating bladder cancer and solid tumors
|
|
US20220412979A1
(en)
|
2018-10-29 |
2022-12-29 |
Genocea Biosciences, Inc. |
Treatment methods
|
|
US20220008346A1
(en)
|
2018-10-30 |
2022-01-13 |
Vanderbilt University |
Graft copolymers, methods of forming graft copolymers, and methods of use thereof
|
|
WO2020092617A1
(en)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Dc-sign antibody conjugates comprising sting agonists
|
|
EP3901161A4
(en)
*
|
2019-01-10 |
2022-03-23 |
Nankai University |
CYCLIC DINUCLEOTIDE PRODRUG MOLECULE, METHOD OF PRODUCTION THEREOF AND APPLICATION THEREOF
|
|
US20220168415A1
(en)
|
2019-03-21 |
2022-06-02 |
Codiak Biosciences, Inc. |
Extracellular vesicles for vaccine delivery
|
|
CN113747925A
(zh)
|
2019-03-21 |
2021-12-03 |
科迪亚克生物科学公司 |
胞外囊泡缀合物及其用途
|
|
EP3941607A1
(en)
|
2019-03-21 |
2022-01-26 |
Codiak BioSciences, Inc. |
Process for preparing extracellular vesicles
|
|
WO2020205688A1
(en)
|
2019-04-04 |
2020-10-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
|
MA55805A
(fr)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V Inc |
Métodes de modulation de l'activité immunitaire
|
|
AU2020267486A1
(en)
|
2019-05-09 |
2021-11-11 |
Aligos Therapeutics, Inc. |
Modified cyclic dinucleoside compounds as STING modulators
|
|
WO2021003445A1
(en)
|
2019-07-03 |
2021-01-07 |
Codiak Biosciences, Inc. |
Extracellular vesicles targeting t cells and uses thereof
|
|
US11155567B2
(en)
|
2019-08-02 |
2021-10-26 |
Mersana Therapeutics, Inc. |
Sting agonist compounds and methods of use
|
|
AU2020328507A1
(en)
|
2019-08-12 |
2022-03-17 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
|
|
EP4034081A1
(en)
|
2019-09-25 |
2022-08-03 |
Codiak BioSciences, Inc. |
Extracellular vesicle compositions
|
|
KR20220094221A
(ko)
|
2019-09-25 |
2022-07-05 |
코디악 바이오사이언시즈, 인크. |
종양의 치료를 위한 il-12 디스플레잉 엑소좀과 조합된 sting 효능제 포함 엑소좀
|
|
EP4034276A1
(en)
|
2019-09-25 |
2022-08-03 |
Codiak BioSciences, Inc. |
Methods of producing extracellular vesicles
|
|
US20230241089A1
(en)
|
2019-09-25 |
2023-08-03 |
Codiak Biosciences, Inc. |
Sting agonist comprising exosomes for treating neuroimmunological disorders
|
|
AU2020358726A1
(en)
|
2019-10-01 |
2022-04-07 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
WO2021074695A1
(en)
|
2019-10-16 |
2021-04-22 |
Avacta Life Sciences Limited |
PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
|
|
WO2021113679A1
(en)
|
2019-12-06 |
2021-06-10 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
|
EP4106819A1
(en)
|
2020-02-21 |
2022-12-28 |
Silverback Therapeutics, Inc. |
Nectin-4 antibody conjugates and uses thereof
|
|
AU2021226023A1
(en)
|
2020-02-28 |
2022-09-15 |
Tallac Therapeutics, Inc. |
Transglutaminase-mediated conjugation
|
|
EP4117717A1
(en)
|
2020-03-13 |
2023-01-18 |
Codiak BioSciences, Inc. |
Extracellular vesicles for treating neurological disorders
|
|
CA3171623A1
(en)
|
2020-03-20 |
2021-09-23 |
Codiak Biosciences, Inc. |
Extracellular vesicles for therapy
|
|
TW202200136A
(zh)
|
2020-04-10 |
2022-01-01 |
日商小野藥品工業股份有限公司 |
癌治療方法
|
|
US20230149560A1
(en)
|
2020-04-20 |
2023-05-18 |
Massachusetts Institute Of Technology |
Lipid compositions for delivery of sting agonist compounds and uses thereof
|
|
CA3178464A1
(en)
|
2020-05-15 |
2021-11-18 |
Immunesensor Therapeutics, Inc. |
Sting agonist combination treatments with immune checkpoint inhibitors
|
|
WO2021237100A1
(en)
|
2020-05-21 |
2021-11-25 |
Codiak Biosciences, Inc. |
Methods of targeting extracellular vesicles to lung
|
|
WO2021252904A1
(en)
|
2020-06-11 |
2021-12-16 |
Massachusetts Institute Of Technology |
Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy
|
|
CA3183993A1
(en)
|
2020-07-01 |
2022-01-06 |
Peter R. Baum |
Anti-asgr1 antibody conjugates and uses thereof
|
|
CN111909223A
(zh)
*
|
2020-07-17 |
2020-11-10 |
清华大学 |
环二核苷酸共价修饰物及其制备方法和应用
|
|
US20230366794A1
(en)
|
2020-09-23 |
2023-11-16 |
Codiak Biosciences, Inc. |
Process for preparing extracellular vesicles
|
|
US20240082389A1
(en)
|
2020-09-23 |
2024-03-14 |
Lonza Sales Ag |
Methods of producing extracellular vesicles
|
|
WO2022066928A2
(en)
|
2020-09-23 |
2022-03-31 |
Codiak Biosciences, Inc. |
Process for preparing extracellular vesicles
|
|
WO2022066883A1
(en)
|
2020-09-23 |
2022-03-31 |
Codiak Biosciences, Inc. |
Extracellular vesicles comprising kras antigens and uses thereof
|
|
TW202227099A
(zh)
*
|
2020-10-20 |
2022-07-16 |
大陸商泰勵生物科技（上海）有限公司 |
多功能環二核苷酸及其用途
|
|
KR102466750B1
(ko)
|
2020-10-23 |
2022-11-15 |
아주대학교산학협력단 |
인돌리진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물
|
|
US20220168330A1
(en)
|
2020-11-09 |
2022-06-02 |
Takeda Pharmaceutical Company Limited |
Antibody drug conjugates
|
|
CA3201844A1
(en)
|
2020-12-17 |
2022-06-23 |
William W. Bachovchin |
Fap-activated radiotheranostics, and uses related thereto
|
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
|
AU2022315305A1
(en)
|
2021-07-23 |
2024-02-01 |
Immunesensor Therapeutics, Inc. |
Sting agonist combination treatments with cytokines
|
|
WO2023056468A1
(en)
|
2021-09-30 |
2023-04-06 |
Codiak Biosciences, Inc. |
Extracellular vesicle comprising cholesterol tagged sting-agonist
|
|
TW202334196A
(zh)
|
2021-10-07 |
2023-09-01 |
英商阿法克塔生命科學有限公司 |
Pd-l1結合多肽
|
|
WO2023170606A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|